<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7768">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890721</url>
  </required_header>
  <id_info>
    <org_study_id>SKY0402C316</org_study_id>
    <nct_id>NCT00890721</nct_id>
  </id_info>
  <brief_title>Study of Pain Control in Hemorrhoidectomy</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will get an injection of either SKY0402 or placebo during hemorrhoid surgery, and
      their pain and pain medicine use will be monitored.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours for Subjects Receiving SKY0402 vs. Placebo.</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain and respond to the following question: &quot;On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain are you having right now?&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Adverse Events Through 72 Hours or Serious Adverse Events Through 30 Days</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">189</enrollment>
  <condition>Hemorrhoid</condition>
  <arm_group>
    <arm_group_label>SKY0402</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the hemorrhoidectomy, 30cc of SKY0402 is injected into the wound.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During the hemorrhoidectomy, 30cc Placebo injected into the wound.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SKY0402</intervention_name>
    <description>During the operation, 30cc of SKY0402 are injected into the wound.</description>
    <arm_group_label>SKY0402</arm_group_label>
    <other_name>EXPAREL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>During the hemorrhoidectomy, 30cc Placebo injected into the wound.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>saline 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years of age at the Screening visit

          -  American Society of Anesthesiologists (ASA) class 1-3

          -  Scheduled to have a two or three column excisional hemorrhoidectomy under general
             anesthesia using the Milligan-Morgan technique

          -  For female subjects, surgically sterile or at least two years menopausal, or using an
             acceptable method of birth control; must have a documented negative blood or urine
             pregnancy test within 24 hours before surgery

          -  Clinical lab values less than or equal to twice the upper limit of normal or, if
             abnormal, deemed not clinically significant per the Investigator.

          -  Ability to understand the requirements of the study, provide written informed
             consent, abide by the study restrictions, and agree to return for the required
             assessments

          -  Able to speak, read, and understand the language of all subject-facing documents,
             including the ICF and study questionnaires

          -  Able and willing to comply with all study visits and procedures

        Exclusion Criteria:

          -  Single-column hemorrhoidectomy or hemorrhoidectomy without an internal component

          -  Body weight less than 50 kilograms (110 pounds)

          -  History of hypersensitivity or idiosyncratic reactions or amide-type local
             anesthetics, opioids, or propofol

          -  Current painful physical condition or concurrent surgery other than hemorrhoids that
             may require analgesic treatment (such as non-steroidal anti-inflammatory drug
             [NSAID], opioid, selective serotonin reuptake inhibitor [SSRI], tricyclic
             antidepressant, gabapentin, pregabalin) in the postoperative period for pain that is
             not strictly related to the hemorrhoidectomy procedure and may confound the
             postoperative assessments

          -  Concurrent fissurectomy

          -  Use of any NSAID including selective COX-2 inhibitor, opioid, SSRI, tricyclic
             antidepressant, gabapentin, or pregabalin within three days of surgery

          -  Use of acetaminophen within 24 hours of surgery

          -  Chronic users of analgesic medications, including taking opioid medications for more
             than 14 days in the last 3 months, or non-opioid pain medications more than 5 times
             per week

          -  History of, suspected, or known addiction to or abuse of drugs or alcohol within the
             past two years

          -  Current use of glucocorticosteroids or use of glucocorticoids within one month of
             enrollment into this study

          -  HIV infection or hepatitis

          -  Currently pregnant, nursing, or planning to become pregnant during the course of the
             study or within one month of study drug administration

          -  Any psychiatric, psychological, medical, or laboratory condition that the
             investigator feels makes the subject an inappropriate candidate for this clinical
             trial

          -  Subjects who have received another investigational drug within the longer of the last
             30 days or 10 elimination half-lives

          -  Previous participation in a SKY0402 study

          -  Failure to pass drug and alcohol screen
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zbigniew Śledziński, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Surgery, Transplantology and Endocrinology Department, Gdansk</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prof. Zbigniew Śledziński</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 3, 2013</lastchanged_date>
  <firstreceived_date>April 28, 2009</firstreceived_date>
  <firstreceived_results_date>November 22, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemorrhoid</keyword>
  <keyword>Hemorrhoidectomy</keyword>
  <keyword>Postoperative pain</keyword>
  <keyword>Analgesia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhoids</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SKY0402</title>
          <description>During the hemorrhoidectomy, 30cc of SKY0402 is injected into the wound.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>During the hemorrhoidectomy, 30cc Placebo injected into the wound.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SKY0402</title>
          <description>During the hemorrhoidectomy, 30cc of SKY0402 is injected into the wound.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>During the hemorrhoidectomy, 30cc Placebo injected into the wound.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="95"/>
                <measurement group_id="B2" value="94"/>
                <measurement group_id="B3" value="189"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="86"/>
                <measurement group_id="B2" value="86"/>
                <measurement group_id="B3" value="172"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="48" spread="12.2"/>
                <measurement group_id="B2" value="48.7" spread="12"/>
                <measurement group_id="B3" value="48.4" spread="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="32"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="59"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="63"/>
                <measurement group_id="B2" value="67"/>
                <measurement group_id="B3" value="130"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Poland</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
                <measurement group_id="B2" value="36"/>
                <measurement group_id="B3" value="72"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Serbia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="50"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Georgia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="67"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours for Subjects Receiving SKY0402 vs. Placebo.</title>
        <description>To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain and respond to the following question: “On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain are you having right now?”</description>
        <time_frame>72 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>SKY0402</title>
            <description>During the hemorrhoidectomy, 30cc of SKY0402 is injected into the wound.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>During the hemorrhoidectomy, 30cc Placebo injected into the wound.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="94"/>
                  <measurement group_id="O2" value="93"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours for Subjects Receiving SKY0402 vs. Placebo.</title>
            <description>To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain and respond to the following question: “On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain are you having right now?”</description>
            <units>units on a scale*hr</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="141.8" spread="10.7"/>
                  <measurement group_id="O2" value="202.5" spread="10.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Adverse Events Through 72 Hours or Serious Adverse Events Through 30 Days</title>
        <time_frame>30 days</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SKY0402</title>
          <description>During the hemorrhoidectomy, 30cc of SKY0402 is injected into the wound.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>During the hemorrhoidectomy, 30cc Placebo injected into the wound.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Painful defaecation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive Medical Director</name_or_title>
      <organization>Pacira Pharmaceuticals, Inc.</organization>
      <phone>203-837-6500</phone>
      <email>ErolOnel@pacira.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
